ArticleBMC women's health2026
Incidence and remission of endometriosis in Germany based on prevalence data from 35 million patients from the statutory health insurance.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic gynecological disease that can potentially develop as early as birth and can restrict the life of the patient. With the increasing prevalence of endometriosis in Germany, it has recently gained attention and priority for consideration. While numerous studies have examined endometriosis in Germany and other countries, studies on its incidence and remission rates are rare. Therefore, this study aimed to estimate the incidence and remission rates of endometriosis based on its age-specific prevalence in German women from 2012 to 2022.This study utilized data from the Central Institute (Zi) for Statutory Health Insurance (SHI) in Germany [1], which observed more than 35 million SHI-insured adolescents and women aged ≥ 10 years in 2012 and 2022, to determine the age-specific prevalence of ascertained diagnoses of endometriosis. The Illness-Death Model was used to estimate the incidence and remission rates of endometriosis. The estimation is based on a bootstrapping approach with 5000 replicates-samples. Results are the median incidence and remission rates, reported with 95% confidence intervals (CIs) based on 2.5% and 97.5% percentiles-quantiles, which quantify the uncertainty of the estimated incidence and remission rates.The bootstrapping approach estimated the incidence (median incidence across all bootstrap samples) about 1.73 per 1,000 person-years at around age of 32 years, and the highest remission rate was about 70.04 at the age of 52 years. The estimated 95% (CI) for the incidence and remission rates were (95% CI 1.71-1.78) and (95% CI 68.1-75.0), respectively.The Illness-Death Model and the prevalence of endometriosis from the Zi enabled the incidence rate of ascertained endometriosis for German women to be estimated. This study was the first to estimate the remission rate of endometriosis in Germany, aiming to better understand the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.